Structure-Based Virtual Screening and Functional Validation of Potential Hit Molecules Targeting the SARS-CoV-2 Main Protease.


Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
25 11 2022
Historique:
received: 29 09 2022
revised: 10 11 2022
accepted: 12 11 2022
entrez: 23 12 2022
pubmed: 24 12 2022
medline: 27 12 2022
Statut: epublish

Résumé

The recent global health emergency caused by the coronavirus disease 2019 (COVID-19) pandemic has taken a heavy toll, both in terms of lives and economies. Vaccines against the disease have been developed, but the efficiency of vaccination campaigns worldwide has been variable due to challenges regarding production, logistics, distribution and vaccine hesitancy. Furthermore, vaccines are less effective against new variants of the SARS-CoV-2 virus and vaccination-induced immunity fades over time. These challenges and the vaccines' ineffectiveness for the infected population necessitate improved treatment options, including the inhibition of the SARS-CoV-2 main protease (M

Identifiants

pubmed: 36551182
pii: biom12121754
doi: 10.3390/biom12121754
pmc: PMC9775371
pii:
doi:

Substances chimiques

3C-like proteinase, SARS-CoV-2 EC 3.4.22.-
Antiviral Agents 0
Biological Products 0
Losartan JMS50MPO89
Coronavirus Protease Inhibitors 0
Coronavirus 3C Proteases EC 3.4.22.28

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Biomedicines. 2022 May 04;10(5):
pubmed: 35625804
Nucleic Acids Res. 2021 Jan 8;49(D1):D1388-D1395
pubmed: 33151290
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
Biochem Biophys Res Commun. 2021 Jan 29;538:173-179
pubmed: 33309272
F1000Res. 2020 Feb 21;9:129
pubmed: 32194944
Curr Top Med Chem. 2017;17(14):1631-1639
pubmed: 27852201
Antiviral Res. 2022 Nov;207:105419
pubmed: 36155070
J Pharm Pharm Sci. 2021;24:390-399
pubmed: 34319871
Virus Res. 2008 Apr;133(1):63-73
pubmed: 17397958
Infect Dis Model. 2020 Feb 11;5:248-255
pubmed: 32099934
PeerJ. 2015 Apr 23;3:e882
pubmed: 25922789
Bioinformatics. 2012 Jun 1;28(11):1540-1
pubmed: 22539672
Cell Res. 2022 May;32(5):498-500
pubmed: 35292745
Mayo Clin Proc. 2020 Jun;95(6):1296-1297
pubmed: 32402512
J Virol. 2020 Dec 9;95(1):
pubmed: 33055254
J Biol Chem. 2011 Mar 11;286(10):8545-8554
pubmed: 21193396
Int J Mol Sci. 2021 Jan 12;22(2):
pubmed: 33445497
Cell Discov. 2020 Oct 29;6(1):77
pubmed: 33298897
Commun Chem. 2022;5(1):117
pubmed: 36187754
Planta Med. 2006 Apr;72(5):424-9
pubmed: 16557456
J Infect Chemother. 2020 Jun;26(6):625-632
pubmed: 32362440
Nucleic Acids Res. 2021 Jan 8;49(D1):D437-D451
pubmed: 33211854
Lebensm Wiss Technol. 2022 Jan 15;154:112684
pubmed: 34720187
Pathogens. 2020 Mar 04;9(3):
pubmed: 32143502
Sci Rep. 2017 Mar 03;7:42717
pubmed: 28256516
JAMA Netw Open. 2022 Mar 1;5(3):e222735
pubmed: 35294537
Nucleic Acids Res. 2015 Jul 1;43(W1):W448-54
pubmed: 25855812
Bioinformatics. 2021 Apr 1;36(22-23):5545-5547
pubmed: 33275143
Antioxidants (Basel). 2020 Aug 13;9(8):
pubmed: 32823497
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Theor Biol Med Model. 2013 Oct 24;10:63
pubmed: 24156411
Science. 2020 Apr 24;368(6489):409-412
pubmed: 32198291
Nucleic Acids Res. 2021 Jul 2;49(W1):W5-W14
pubmed: 33893803
Med Res Rev. 2022 Mar;42(2):744-769
pubmed: 34697818
J Biomol Struct Dyn. 2021 May;39(8):2679-2692
pubmed: 32266873
Microbiol Spectr. 2022 Aug 31;10(4):e0255921
pubmed: 35758897
J Biomol Struct Dyn. 2021 Jun;39(9):3409-3418
pubmed: 32306836
ACS Sens. 2017 Jun 23;2(6):729-734
pubmed: 28670623
J Biomol Struct Dyn. 2021 Apr;39(7):2673-2678
pubmed: 32248766
Drug Dev Res. 2020 Nov;81(7):768-770
pubmed: 32356926
Biochemistry. 2008 Mar 18;47(11):3534-43
pubmed: 18293931
J Chem Inf Model. 2011 Oct 24;51(10):2778-86
pubmed: 21919503
J Cheminform. 2020 May 27;12(1):37
pubmed: 33430966
J Nat Prod. 2004 Apr;67(4):693-6
pubmed: 15104507
J Biomol Struct Dyn. 2022 Jan;40(1):136-142
pubmed: 32811367
Bioorg Med Chem. 2022 Oct 15;72:117003
pubmed: 36103795
BMC Cardiovasc Disord. 2022 Mar 19;22(1):116
pubmed: 35305551
Hypertension. 2021 Mar 3;77(3):833-842
pubmed: 33423528

Auteurs

Balasubramanian Moovarkumudalvan (B)

Division of Genomics and Translational Biomedicine, College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar Foundation, Education City, Doha P.O. Box 34110, Qatar.

Anupriya Madhukumar Geethakumari (AM)

Division of Biological and Biomedical Sciences, College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar Foundation, Education City, Doha P.O. Box 34110, Qatar.

Ramya Ramadoss (R)

Biological Sciences, Carnegie Mellon University-Qatar, Qatar Foundation, Education City, Doha P.O. Box 24866, Qatar.

Kabir H Biswas (KH)

Division of Biological and Biomedical Sciences, College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar Foundation, Education City, Doha P.O. Box 34110, Qatar.

Borbala Mifsud (B)

Division of Genomics and Translational Biomedicine, College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar Foundation, Education City, Doha P.O. Box 34110, Qatar.
William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH